• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by CEO, Pres., CFO, Treas & Secty Francis Knuettel Ii

    4/15/25 9:30:47 PM ET
    $CHRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CHRO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Francis Knuettel II

    (Last) (First) (Middle)
    C/O CHROMOCELL THERAPEUTICS CORPORATION
    4400 ROUTE 9 SOUTH, SUITE 1000

    (Street)
    FREEHOLD NJ 07728

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Channel Therapeutics Corp [ CHRO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    CEO, Pres., CFO, Treas & Secty
    3. Date of Earliest Transaction (Month/Day/Year)
    04/11/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option(1) $1.35 04/11/2025(1) A 53,988(1) (1) 04/11/2035 Common Stock 53,988(1) (1) 430,736(1) D
    Explanation of Responses:
    1. On April 11, 2025, the Reporting Person was granted stock options to purchase 53,988 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction.
    /s/ Francis Knuettel II 04/15/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CHRO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CHRO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CHRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Channel Therapeutics Announces Positive Efficacy Results for the Treatment of Eye Pain Using its NaV1.7 Inhibitor in Multiple Preclinical In Vivo Models

      FREEHOLD, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it has achieved its predefined endpoints in two pre-clinical animal models of the Company's eye drop formulations ("CT2000") for the treatment of both acute ocular pain as well as chronic ocular surface pain commonly associated with dry eye disease. "We are very pleased with the results of these animal efficacy studies, which adds to the Depot formulation study results announced in December 2024, demonstrating a viable path forward in treating both post-surgical pain and ch

      5/14/25 8:00:00 AM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules

      FREEHOLD, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today advises that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on March 27, 2025, the audited financial statements contained an audit opinion from its independent registered public accounting firm that included a going concern emphasis of matter paragraph. Release of this information is required by Sections 410(h) and 610(b) of the NYSE American LLC Company Guide. This announcement does not rep

      5/1/25 5:00:00 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

      Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMI™ ZELSUVMI is an FDA-designated novel drug and the first and only prescription medication approved for the treatment of Molluscum contagiosum infections administered at home by parents, patients, and caregivers Ligand is entitled to a 13% royalty on worldwide sales of ZELSUVMI Transaction is expected to close in the summer of 2025 JUPITER, Fla. and FREEHOLD, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated ("Ligand") (NASDAQ:LGND) and Channel Therapeutics Corporation ("Channel") (NYSE:CHRO), a pioneer i

      4/17/25 6:00:00 AM ET
      $CHRO
      $LGND
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $CHRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CHRO
    SEC Filings

    See more

    $CHRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $CHRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Simmons Chia-Lin

      4 - Channel Therapeutics Corp (0001919246) (Issuer)

      4/15/25 9:31:27 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CEO, Pres., CFO, Treas & Secty Francis Knuettel Ii

      4 - Channel Therapeutics Corp (0001919246) (Issuer)

      4/15/25 9:30:47 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Davis Todd C

      4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

      11/15/24 4:22:20 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFM14C filed by Channel Therapeutics Corporation

      DEFM14C - Channel Therapeutics Corp (0001919246) (Filer)

      5/27/25 5:07:58 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Channel Therapeutics Corporation

      10-Q - Channel Therapeutics Corp (0001919246) (Filer)

      5/13/25 4:31:08 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form PREM14C filed by Channel Therapeutics Corporation

      PREM14C - Channel Therapeutics Corp (0001919246) (Filer)

      5/9/25 5:30:35 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Chromocell Therapeutics Corporation

      SC 13G/A - Chromocell Therapeutics Corp (0001919246) (Subject)

      11/13/24 4:05:24 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Chromocell Therapeutics Corporation

      SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)

      3/4/24 4:07:02 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Chromocell Therapeutics Corporation

      SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)

      3/1/24 5:19:37 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Malamut Richard bought $9,825 worth of shares (10,400 units at $0.94) (SEC Form 4)

      4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

      9/16/24 4:56:55 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEO, Pres., CFO, Treas & Secty Francis Knuettel Ii bought $5,044 worth of shares (5,200 units at $0.97) (SEC Form 4)

      4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

      9/16/24 4:55:23 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEO, Pres., CFO, Treas & Secty Francis Knuettel Ii bought $10,955 worth of shares (12,000 units at $0.91) (SEC Form 4)

      4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

      9/12/24 5:35:41 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care